Australia’s Therapeutic Goods Administration (TGA) is taking a phased approach to regulatory compliance, prioritizing higher-risk medical devices first and gradually expanding requirements to lower-risk categories in the coming years. This structured rollout is designed to manage the complexity of implementation while ensuring that patients and healthcare systems benefit from stronger safeguards at the earliest possible stage.